Recent studies have converged on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic communication. While GLP agonists are increasingly employed for treating type 2 T2DM, their potential consequences on reward circuits, specifically govern